Terns Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript
Good afternoon, everyone, and thanks for joining us today for the Terns Pharmaceutical fireside chat at the Cowen Oncology Innovation Summit. I'm Covering Analyst Ritu Baral. And with us from Terns today, we have CEO Senthil Sundaram.
Sent, thank you so much for joining us today to discuss the Terns's oncology portfolio with a focus on TERN-701.
Great. Thank you for having me. Looking forward to it.
So I really want to give us enough time to go over 701, which is sort of a new point of intense investor conversation for Terns as a story. You do have other programs. Most know you as historically a NASH play, but there is a growing interest, a growing proportion of investors that looking at your STAMP inhibitor, 701 and almost exclusively, your STAMP inhibitor, 701, as its own promising value driver that could potentially support your entire valuation.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |